[go: up one dir, main page]

CL2018002793A1 - Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control - Google Patents

Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control

Info

Publication number
CL2018002793A1
CL2018002793A1 CL2018002793A CL2018002793A CL2018002793A1 CL 2018002793 A1 CL2018002793 A1 CL 2018002793A1 CL 2018002793 A CL2018002793 A CL 2018002793A CL 2018002793 A CL2018002793 A CL 2018002793A CL 2018002793 A1 CL2018002793 A1 CL 2018002793A1
Authority
CL
Chile
Prior art keywords
control point
cancer therapy
point inhibitor
oncolytic virus
virus combined
Prior art date
Application number
CL2018002793A
Other languages
English (en)
Inventor
Barbara Leuchs
Jean Rommelaere
Michael Dahm
Antonio Marchini
Assia Angelova
Dirk JÄGER
Wolfgang Wick
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Publication of CL2018002793A1 publication Critical patent/CL2018002793A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA EN LA CUAL UN INHIBIDOR DE PUNTO DE CONTROL SE COMBINA CON UN VIRUS ONCOLÍTICO Y AL USO DE DICHA COMBINACIÓN PARA EL TRATAMIENTO DE CÁNCER.
CL2018002793A 2016-04-01 2018-10-01 Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control CL2018002793A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163555 2016-04-01
EP16020193.5A EP3225253A1 (en) 2016-04-01 2016-05-27 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
CL2018002793A1 true CL2018002793A1 (es) 2019-02-01

Family

ID=55650316

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002793A CL2018002793A1 (es) 2016-04-01 2018-10-01 Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control

Country Status (16)

Country Link
US (2) US11027013B2 (es)
EP (1) EP3225253A1 (es)
JP (1) JP6689400B2 (es)
KR (1) KR102195055B1 (es)
CN (1) CN109069601B (es)
AU (1) AU2017242089B2 (es)
BR (1) BR112018069927A2 (es)
CA (1) CA3019634A1 (es)
CL (1) CL2018002793A1 (es)
EA (1) EA037354B1 (es)
IL (1) IL261554B (es)
LT (1) LT3436058T (es)
MX (1) MX2018010709A (es)
SG (1) SG11201807977XA (es)
WO (1) WO2017167626A1 (es)
ZA (1) ZA201805548B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009204A1 (en) * 2017-03-15 2020-01-09 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
EP4063859A1 (en) 2017-04-28 2022-09-28 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
CN109022616B (zh) * 2018-07-25 2021-11-12 广州烨善生物科技有限公司 一种检测溶瘤病毒的探针及其应用
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
CA3128064A1 (en) * 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
EP3930851A4 (en) * 2019-02-28 2023-03-29 Shattuck Labs, Inc. Combination therapies
EP4028052A1 (en) * 2019-09-10 2022-07-20 Novocure GmbH A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
WO2021127254A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN111154806A (zh) * 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
WO2024207425A1 (en) * 2023-04-07 2024-10-10 Virogin Biotech (Shanghai) Ltd. Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer
WO2024216390A1 (en) * 2023-04-20 2024-10-24 University Health Network Methods to treat glioma in subjects with defined tumour microenvironment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7179456B2 (en) * 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
ES2402138T3 (es) * 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2266587A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oncolytic virotherapy for prevention of tumor recurrence
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
EP2366398A1 (en) 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
EP2397542A1 (en) 2010-06-17 2011-12-21 Deutsches Krebsforschungszentrum Modified parvovirus having enhanced anti-tumour efficacy
EP2404609A1 (en) * 2010-07-07 2012-01-11 Deutsches Krebsforschungszentrum Use of parvovirus for eliminating cancer stem cells (CSCs)
EP2535055A1 (en) * 2011-06-15 2012-12-19 Deutsches Krebsforschungszentrum Oncolytic virotherapy for therapy of bone cancer
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
EP2829284A1 (en) * 2013-07-22 2015-01-28 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
DK3142690T3 (da) 2014-05-13 2022-05-09 Bavarian Nordic As Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist
JP6843736B2 (ja) * 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
EP3108892A1 (en) * 2015-06-23 2016-12-28 Deutsches Krebsforschungszentrum Parvovirus formulation for treating tumors

Also Published As

Publication number Publication date
ZA201805548B (en) 2019-11-27
AU2017242089A1 (en) 2018-08-30
US20210228714A1 (en) 2021-07-29
EA201891679A1 (ru) 2019-04-30
CN109069601A (zh) 2018-12-21
WO2017167626A1 (en) 2017-10-05
US11027013B2 (en) 2021-06-08
US20190117768A1 (en) 2019-04-25
JP6689400B2 (ja) 2020-04-28
MX2018010709A (es) 2019-01-14
KR20180127468A (ko) 2018-11-28
LT3436058T (lt) 2020-02-10
JP2019510769A (ja) 2019-04-18
EP3225253A1 (en) 2017-10-04
AU2017242089B2 (en) 2019-08-15
IL261554B (en) 2022-05-01
EA037354B1 (ru) 2021-03-17
NZ745264A (en) 2020-10-30
CA3019634A1 (en) 2017-10-05
CN109069601B (zh) 2022-05-10
SG11201807977XA (en) 2018-10-30
IL261554A (en) 2018-10-31
KR102195055B1 (ko) 2020-12-24
US11964015B2 (en) 2024-04-23
BR112018069927A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
ECSP17073743A (es) Moduladores de k-ras
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
MX2018003491A (es) Represores de htt y usos de estos.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2017013802A (es) Métodos para tratar el cáncer.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.